vatalanib has been researched along with ici 118551 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (ici 118551) | Trials (ici 118551) | Recent Studies (post-2010) (ici 118551) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 836 | 31 | 106 |
| Protein | Taxonomy | vatalanib (IC50) | ici 118551 (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0007 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Ji, Y; Li, K; Xiao, X; Xu, T; Zheng, S | 1 |
1 other study(ies) available for vatalanib and ici 118551
| Article | Year |
|---|---|
Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Cell Survival; Culture Media, Serum-Free; Endothelial Cells; Hemangioma; Human Umbilical Vein Endothelial Cells; Humans; Phthalazines; Propanolamines; Propranolol; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |